![]() Lowering drug prices continues to be a bipartisan issue as both parties aim to offer Americans more affordable prices. Despite this, policy risks are on the rise. Generic drug makers are expected to continue to struggle due to lower-cost emerging market competition. Recent FDA recommendations, such as approval for a fourth booster dose for those aged 50 or older, suggests we may be moving in this direction. If that were to happen, it would prove to be very lucrative for pharmaceutical companies, as it would generate recurring sales. Should COVID-19 variants continue to arise getting a COVID-19 vaccine could become a seasonal phenomenon, much like the flu vaccine. ![]() COVID-19 therapies, oncology and immunology are essential aspects of pharmaceutical companies. The outlook for the Pharmaceuticals sub-industry is positive as the world returns to normalcy and demand for electives and improved medical utilization. ![]() Silo Pharma Inc does not currently pay a dividend. There are not analysts providing consensus earnings estimates for the current fiscal year. Year-over-year quarterly sales growth most recently was %. Silo Pharma Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Silo Pharma Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Read on to find out how ( SILO) grades on certain investment factors and determine whether it meets your investment needs.Īs of April 26, 2023, Silo Pharma Inc had a $6.6 million market capitalization, putting it in the 9th percentile of companies in the Pharmaceuticals industry. Learn more about whether Silo Pharma Inc is a good stock to buy or sell based on recent news as well as its key financial metrics.
0 Comments
Leave a Reply. |